FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012318170> ?p ?o ?g. }

• W2012318170 endingPage "132" @default.
• W2012318170 startingPage "126" @default.
• W2012318170 abstract "Both alcohol withdrawal syndrome (AWS) and benzodiazepines can cause delirium. Benzodiazepine-associated delirium can complicate AWS and prolong hospitalization. Benzodiazepine delirium can be diagnosed with flumazenil, a GABA-A receptor antagonist. By reversing the effects of benzodiazepines, flumazenil is theorized to exacerbate symptoms of AWS and precludes its use. For patients being treated for alcohol withdrawal, flumazenil can diagnose and treat benzodiazepine delirium without precipitating serious or life-threatening adverse events. Hospital admission records were retrospectively reviewed for patients with the diagnosis of AWS who received both benzodiazepines and flumazenil from December 2006 to June 2012 at a university-affiliated inpatient toxicology center. The day of last alcohol consumption was estimated from available blood alcohol content or subjective history. Corresponding benzodiazepine, flumazenil, and adjunctive sedative pharmacy records were reviewed, as were demographic, clinical course, and outcome data. Eighty-five patients were identified (average age 50.3 years). Alcohol concentrations were detectable for 42 patients with average 261 mg/dL (10-530 mg/dL). Eighty patients were treated with adjunctive agents for alcohol withdrawal including antipsychotics (n = 57), opioids (n = 27), clonidine (n = 35), and phenobarbital (n = 23). Average time of flumazenil administration was 4.7 days (1-11 days) after abstinence, and average dose was 0.5 mg (0.2-1 mg). At the time of flumazenil administration, delirium was described as hypoactive (n = 21), hyperactive (n = 15), mixed (n = 41), or not specified (n = 8). Response was not documented in 11 cases. Sixty-two (72.9 %) patients had significant objective improvement after receiving flumazenil. Fifty-six patients required more than one dose (average 5.6 doses). There were no major adverse events and minor adverse effects included transiently increased anxiety in two patients: 1 patient who received 0.5 mg on abstinence day 2 and another patient who received 0.2 mg flumazenil on abstinence day 11. This is the largest series diagnosing benzodiazepine delirium after AWS in patients receiving flumazenil. During the treatment of AWS, if delirium is present on day 5, a test dose of flumazenil may be considered to establish benzodiazepine delirium. With the limited data set often accompanying patients with AWS, flumazenil diagnosed benzodiazepine delirium during the treatment of AWS and improved impairments in cognition and behavior without serious or life-threatening adverse events in our patients." @default.
• W2012318170 created "2016-06-24" @default.
• W2012318170 creator A5000715531 @default.
• W2012318170 creator A5008487793 @default.
• W2012318170 creator A5012629867 @default.
• W2012318170 creator A5027822582 @default.
• W2012318170 creator A5035218517 @default.
• W2012318170 creator A5046384048 @default.
• W2012318170 creator A5054803125 @default.
• W2012318170 creator A5066214719 @default.
• W2012318170 creator A5086494085 @default.
• W2012318170 date "2014-03-12" @default.
• W2012318170 modified "2023-10-06" @default.
• W2012318170 title "Safety and Efficacy of Flumazenil for Reversal of Iatrogenic Benzodiazepine-Associated Delirium Toxicity During Treatment of Alcohol Withdrawal, a Retrospective Review at One Center" @default.
• W2012318170 cites W1968514574 @default.
• W2012318170 cites W1975809347 @default.
• W2012318170 cites W1978088297 @default.
• W2012318170 cites W1985664398 @default.
• W2012318170 cites W2003605191 @default.
• W2012318170 cites W2007774024 @default.
• W2012318170 cites W2008481910 @default.
• W2012318170 cites W2026354032 @default.
• W2012318170 cites W2047198374 @default.
• W2012318170 cites W2050625435 @default.
• W2012318170 cites W2066736629 @default.
• W2012318170 cites W2068561909 @default.
• W2012318170 cites W2083091419 @default.
• W2012318170 cites W2088959265 @default.
• W2012318170 cites W2090924284 @default.
• W2012318170 cites W2094516340 @default.
• W2012318170 cites W2095722194 @default.
• W2012318170 cites W2097131766 @default.
• W2012318170 cites W2115910406 @default.
• W2012318170 cites W2133974927 @default.
• W2012318170 cites W2145070540 @default.
• W2012318170 cites W2166103222 @default.
• W2012318170 cites W2316866751 @default.
• W2012318170 cites W2317658804 @default.
• W2012318170 cites W2332795863 @default.
• W2012318170 doi "https://doi.org/10.1007/s13181-014-0391-6" @default.
• W2012318170 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4057541" @default.
• W2012318170 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24619543" @default.
• W2012318170 hasPublicationYear "2014" @default.
• W2012318170 type Work @default.
• W2012318170 sameAs 2012318170 @default.
• W2012318170 citedByCount "28" @default.
• W2012318170 countsByYear W20123181702014 @default.
• W2012318170 countsByYear W20123181702015 @default.
• W2012318170 countsByYear W20123181702016 @default.
• W2012318170 countsByYear W20123181702017 @default.
• W2012318170 countsByYear W20123181702018 @default.
• W2012318170 countsByYear W20123181702019 @default.
• W2012318170 countsByYear W20123181702020 @default.
• W2012318170 countsByYear W20123181702021 @default.
• W2012318170 countsByYear W20123181702022 @default.
• W2012318170 countsByYear W20123181702023 @default.
• W2012318170 crossrefType "journal-article" @default.
• W2012318170 hasAuthorship W2012318170A5000715531 @default.
• W2012318170 hasAuthorship W2012318170A5008487793 @default.
• W2012318170 hasAuthorship W2012318170A5012629867 @default.
• W2012318170 hasAuthorship W2012318170A5027822582 @default.
• W2012318170 hasAuthorship W2012318170A5035218517 @default.
• W2012318170 hasAuthorship W2012318170A5046384048 @default.
• W2012318170 hasAuthorship W2012318170A5054803125 @default.
• W2012318170 hasAuthorship W2012318170A5066214719 @default.
• W2012318170 hasAuthorship W2012318170A5086494085 @default.
• W2012318170 hasBestOaLocation W20123181702 @default.
• W2012318170 hasConcept C118552586 @default.
• W2012318170 hasConcept C126322002 @default.
• W2012318170 hasConcept C170493617 @default.
• W2012318170 hasConcept C185592680 @default.
• W2012318170 hasConcept C197934379 @default.
• W2012318170 hasConcept C2776901510 @default.
• W2012318170 hasConcept C2777602617 @default.
• W2012318170 hasConcept C2778173252 @default.
• W2012318170 hasConcept C2778409475 @default.
• W2012318170 hasConcept C2779753318 @default.
• W2012318170 hasConcept C2780873584 @default.
• W2012318170 hasConcept C2781066024 @default.
• W2012318170 hasConcept C42219234 @default.
• W2012318170 hasConcept C55493867 @default.
• W2012318170 hasConcept C71924100 @default.
• W2012318170 hasConceptScore W2012318170C118552586 @default.
• W2012318170 hasConceptScore W2012318170C126322002 @default.
• W2012318170 hasConceptScore W2012318170C170493617 @default.
• W2012318170 hasConceptScore W2012318170C185592680 @default.
• W2012318170 hasConceptScore W2012318170C197934379 @default.
• W2012318170 hasConceptScore W2012318170C2776901510 @default.
• W2012318170 hasConceptScore W2012318170C2777602617 @default.
• W2012318170 hasConceptScore W2012318170C2778173252 @default.
• W2012318170 hasConceptScore W2012318170C2778409475 @default.
• W2012318170 hasConceptScore W2012318170C2779753318 @default.
• W2012318170 hasConceptScore W2012318170C2780873584 @default.
• W2012318170 hasConceptScore W2012318170C2781066024 @default.
• W2012318170 hasConceptScore W2012318170C42219234 @default.
• W2012318170 hasConceptScore W2012318170C55493867 @default.
• W2012318170 hasConceptScore W2012318170C71924100 @default.
• W2012318170 hasIssue "2" @default.

• next